An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

María Laura Acosta-Felquer, Javier Rosa, Enrique R SorianoRheumatology Unit, Internal Medical Services, and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaAbstract: Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α&nbs...

Full description

Bibliographic Details
Main Authors: Acosta-Felquer ML, Rosa J, Soriano ER
Format: Article
Language:English
Published: Dove Medical Press 2016-03-01
Series:Open Access Rheumatology : Research and Reviews
Subjects:
certolizumab pegol
tumour necrosis factor alpha inhibitors
psoriatic arthritis
efficacy
safety.
Online Access:https://www.dovepress.com/an-evidence-based-review-of-certolizumab-pegol-in-the-treatment-of-act-peer-reviewed-article-OARRR

Internet

https://www.dovepress.com/an-evidence-based-review-of-certolizumab-pegol-in-the-treatment-of-act-peer-reviewed-article-OARRR

Similar Items